Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial
Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, p...
Saved in:
| Published in: | PloS one Vol. 11; no. 8; p. e0160257 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Public Library of Science
25.08.2016
Public Library of Science (PLoS) |
| Subjects: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial.
Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency's reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.
There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02).
We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma.
ClinicalTrials.gov NCT01134835. |
|---|---|
| AbstractList | Background
Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial.
Methods
Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency’s reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.
Results
There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02).
Conclusions
We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma.
Trial Registration
ClinicalTrials.gov NCT01134835 BackgroundPeroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial.MethodsSixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency's reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.ResultsThere was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02).ConclusionsWe found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma.Trial registrationClinicalTrials.gov NCT01134835. Background Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial. Methods Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency’s reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis. Results There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02). Conclusions We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma. Trial Registration ClinicalTrials.gov NCT01134835 Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial. Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency's reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis. There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02). We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma. ClinicalTrials.gov NCT01134835. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial.BACKGROUNDPeroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial.Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency's reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.METHODSSixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency's reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02).RESULTSThere was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02).We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma.CONCLUSIONSWe found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma.ClinicalTrials.gov NCT01134835.TRIAL REGISTRATIONClinicalTrials.gov NCT01134835. |
| Author | Bailey, H. Hodgson, D. B. Shaw, D. E. Anderson, J. R. Mortimer, K. Knox, A. J. Harrison, T. W. Pang, L. Smith, K. M |
| AuthorAffiliation | Universite de Bretagne Occidentale, FRANCE 2 Liverpool School of Tropical Medicine, Liverpool, UK and Aintree University Hospital NHS Foundation Trust, Fazakerley, United Kingdom 1 Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom |
| AuthorAffiliation_xml | – name: 2 Liverpool School of Tropical Medicine, Liverpool, UK and Aintree University Hospital NHS Foundation Trust, Fazakerley, United Kingdom – name: 1 Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom – name: Universite de Bretagne Occidentale, FRANCE |
| Author_xml | – sequence: 1 givenname: J. R. surname: Anderson fullname: Anderson, J. R. – sequence: 2 givenname: K. orcidid: 0000-0002-8118-8871 surname: Mortimer fullname: Mortimer, K. – sequence: 3 givenname: L. surname: Pang fullname: Pang, L. – sequence: 4 givenname: K. M surname: Smith fullname: Smith, K. M – sequence: 5 givenname: H. surname: Bailey fullname: Bailey, H. – sequence: 6 givenname: D. B. surname: Hodgson fullname: Hodgson, D. B. – sequence: 7 givenname: D. E. surname: Shaw fullname: Shaw, D. E. – sequence: 8 givenname: A. J. surname: Knox fullname: Knox, A. J. – sequence: 9 givenname: T. W. surname: Harrison fullname: Harrison, T. W. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27560168$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uttu1DAQjVARvcAfILDECy9ZbCdxnD4ghaVApSJW1b5bk9je9cqxlzipRH-r_9FvwstmUVshnjwanzlzZuacJkfOO5UkrwmekawkHzZ-7B3Y2TamZ5gwTIvyWXJCqoymjOLs6EF8nJyGsMG4yDhjL5JjWhYslvCTxFzcgB1hMN4hr9GwVmixqK_T-ztUr7wzYUAL41fWDHAbGyHj0HdjJarDsO7gHNXosx8bq9JP1jiJrsFJ35lbJdHcu6H31sZw2RuwL5PnGmxQr6b3LFl-uVjOv6VXP75ezuurtC0oG9KcAJQAEkNBNWdlJalqIeNAJJYNbTPFNaG0IarUtJQcgFYs1w2usoZTnZ0lb_e0W-uDmJYUBOEkJ0VcRR4Rl3uE9LAR29500P8SHoz4k_D9SkA_mNYqQWimq6wsMcV5znVbYQ26ZCyPMqjiLHJ9nLqNTadkq-LMYB-RPv5xZi1W_kbkVVURXkWC9xNB73-OKgyiM6FV1oJTftzrZjyejUTouyfQf0_35qGiv1IOJ4-A8z2g7X0IvdKijcfdGSAKNFYQLHb-OpCLnb_E5K9YnD8pPvD_t-w3IV_X1g |
| CitedBy_id | crossref_primary_10_3390_diagnostics14171869 crossref_primary_10_4239_wjd_v16_i1_97954 crossref_primary_10_1183_16000617_0095_2019 crossref_primary_10_1097_MCP_0000000000000738 crossref_primary_10_1155_2020_8906968 crossref_primary_10_3389_fimmu_2019_02318 crossref_primary_10_1016_j_jep_2020_112635 crossref_primary_10_1038_s41385_020_00339_6 crossref_primary_10_1111_jcmm_17790 crossref_primary_10_3389_fmed_2017_00104 crossref_primary_10_1016_j_phrs_2021_105821 crossref_primary_10_11131_2018_101306 crossref_primary_10_3390_ijms20205055 crossref_primary_10_1016_j_jaci_2017_05_033 crossref_primary_10_1016_j_bbrc_2020_03_158 crossref_primary_10_3389_fimmu_2020_594433 crossref_primary_10_1016_j_coi_2024_102500 crossref_primary_10_3390_ijms22020805 crossref_primary_10_1155_2017_5134760 crossref_primary_10_1007_s11882_021_01022_x crossref_primary_10_1007_s12016_025_09081_y crossref_primary_10_1111_bph_14465 crossref_primary_10_3390_cells13201688 crossref_primary_10_1111_all_13305 crossref_primary_10_1177_20406223231171556 crossref_primary_10_1002_jcp_27836 crossref_primary_10_1080_02770903_2024_2414342 |
| Cites_doi | 10.1126/science.3283939 10.1016/j.rmed.2009.11.006 10.1164/rccm.200801-060ST 10.1159/000077790 10.1016/S0002-9440(10)63116-1 10.1016/j.jaci.2004.02.036 10.1186/s12931-015-0303-6 10.1056/NEJMoa072761 10.1136/thx.52.6.498 10.1084/jem.20021384 10.1007/s00125-013-2976-z 10.1038/sj.bjp.0705232 10.1164/ajrccm.164.8.2101070 10.1096/fj.04-3309fje 10.1056/NEJMra041001 10.4049/jimmunol.0803504 10.1016/0092-8674(95)90193-0 10.1034/j.1399-3003.1999.14d29.x 10.1136/thx.38.10.760 10.1136/thorax.58.9.778 10.1038/clpt.2009.41 10.1016/j.clpt.2006.03.014 10.1378/chest.115.5.1265 10.1046/j.1365-2222.2003.01777.x 10.1074/jbc.M410616200 |
| ContentType | Journal Article |
| Copyright | 2016 Anderson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Anderson et al 2016 Anderson et al |
| Copyright_xml | – notice: 2016 Anderson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Anderson et al 2016 Anderson et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0160257 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Clinical Trial of Pioglitazone in Asthma |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1814152034 oai_doaj_org_article_123f9377020448fc90faf7664c3e2e86 PMC4999189 4159767781 27560168 10_1371_journal_pone_0160257 |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MR/N005953/1 – fundername: Medical Research Council grantid: MC_G1002462 – fundername: ; grantid: 08-246-02 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV CGR CUY CVF ECM EIF IPNFZ NPM RIG 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP BBORY KM |
| ID | FETCH-LOGICAL-c526t-41aa7aad0a52f8679d2eca38a1d0db2c3e8f122b1e7f27d8aa2964fb093b82f3 |
| IEDL.DBID | FPL |
| ISICitedReferencesCount | 31 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000382258600009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:27 EST 2021 Fri Oct 03 12:43:59 EDT 2025 Tue Nov 04 02:01:02 EST 2025 Sat Sep 27 23:13:57 EDT 2025 Tue Oct 07 07:37:14 EDT 2025 Mon Jul 21 06:01:32 EDT 2025 Tue Nov 18 19:54:12 EST 2025 Sat Nov 29 04:07:55 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c526t-41aa7aad0a52f8679d2eca38a1d0db2c3e8f122b1e7f27d8aa2964fb093b82f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Competing Interests: The authors have declared that no competing interests exist. Conceptualization: AK TH LP KM. Data curation: JA AK TH LP KM DH DS. Formal analysis: JA AK TH LP KM DH DS. Funding acquisition: KM AK TH LP JA DH DS. Investigation: JA AK TH LP KM DH DS. Methodology: AK TH LP KM JA. Project administration: JA KS HB DH. Resources: AK TH. Supervision: TH AK KM. Validation: JA KS HB. Writing – original draft: JA AK TH LP KM. Writing – review & editing: JA AK TH LP KM DH DS. |
| ORCID | 0000-0002-8118-8871 |
| OpenAccessLink | http://dx.doi.org/10.1371/journal.pone.0160257 |
| PMID | 27560168 |
| PQID | 1814152034 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1814152034 doaj_primary_oai_doaj_org_article_123f9377020448fc90faf7664c3e2e86 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4999189 proquest_miscellaneous_1814683861 proquest_journals_1814152034 pubmed_primary_27560168 crossref_citationtrail_10_1371_journal_pone_0160257 crossref_primary_10_1371_journal_pone_0160257 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-25 |
| PublicationDateYYYYMMDD | 2016-08-25 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-25 day: 25 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | D Tripathy (ref30) 2013; 56 L Benayoun (ref4) 2001; 164 R Evans (ref2) 1988; 240 M Hetzel (ref12) 2003; 58 H Yki-Jarvinen (ref14) 2004; 351 AE Dixon (ref19) 2015; 16 EF Juniper (ref25) 1999; 115 A Fogarty (ref27) 2003; 33 ref1 ref16 R Berria (ref29) 2006; 80 H Hammad (ref8) 2004; 164 M Nie (ref3) 2005; 280 EF Juniper (ref23) 1999; 14 ID Pavord (ref21) 2009 BM Forman (ref31) 1995; 83 S Ueki (ref9) 2004; 134 M Spears (ref18) 2009; 86 ID Pavord (ref22) 1997; 52 G Woerly (ref6) 2003; 198 A Malur (ref13) 2009; 182 ref26 A Trifilieff (ref7) 2003; 139 DB Richards (ref17) 2010; 104 ref20 HK Reddel (ref28) 2009; 180 K Yan (ref24) 1983; 38 KS Lee (ref10) 2005; 19 K Honda (ref5) 2004; 113 SE Nissen (ref15) 2007; 356 GB Toews (ref11) 2009 |
| References_xml | – volume: 240 start-page: 889 issue: 4854 year: 1988 ident: ref2 article-title: The steroid and thyroid hormone receptor superfamily publication-title: Science (New York, NY) doi: 10.1126/science.3283939 – ident: ref1 – volume: 104 start-page: 668 issue: 5 year: 2010 ident: ref17 article-title: Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial publication-title: Respiratory medicine doi: 10.1016/j.rmed.2009.11.006 – volume: 180 start-page: 59 issue: 1 year: 2009 ident: ref28 article-title: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200801-060ST – ident: ref20 – volume: 134 start-page: 30 issue: Suppl. 1 year: 2004 ident: ref9 article-title: Peroxisome Proliferator-Activated Receptor γ Regulates Eosinophil Functions: A New Therapeutic Target for Allergic Airway Inflammation publication-title: International archives of allergy and immunology doi: 10.1159/000077790 – volume: 164 start-page: 263 issue: 1 year: 2004 ident: ref8 article-title: Activation of Peroxisome Proliferator-Activated Receptor-{gamma} in Dendritic Cells Inhibits the Development of Eosinophilic Airway Inflammation in a Mouse Model of Asthma publication-title: American Journal of Pathology doi: 10.1016/S0002-9440(10)63116-1 – start-page: 133 year: 2009 ident: ref11 article-title: Asthma and COPD – volume: 113 start-page: 882 issue: 5 year: 2004 ident: ref5 article-title: Peroxisome proliferator-activated receptor [gamma] is expressed in airways and inhibits features of airway remodeling in a mouse asthma model publication-title: Journal of Allergy and Clinical Immunology doi: 10.1016/j.jaci.2004.02.036 – volume: 16 start-page: 1 issue: 1 year: 2015 ident: ref19 article-title: A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity publication-title: Respiratory research doi: 10.1186/s12931-015-0303-6 – volume: 356 start-page: 2457 issue: 24 year: 2007 ident: ref15 article-title: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes publication-title: The New England journal of medicine doi: 10.1056/NEJMoa072761 – volume: 52 start-page: 498 issue: 6 year: 1997 ident: ref22 article-title: The use of induced sputum to investigate airway inflammation publication-title: Thorax doi: 10.1136/thx.52.6.498 – volume: 198 start-page: 411 issue: 3 year: 2003 ident: ref6 article-title: Peroxisome Proliferator-activated Receptors alpha and gamma Down-regulate Allergic Inflammation and Eosinophil Activation publication-title: The Journal of Experimental Medicine doi: 10.1084/jem.20021384 – volume: 56 start-page: 2153 issue: 10 year: 2013 ident: ref30 article-title: Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study publication-title: Diabetologia doi: 10.1007/s00125-013-2976-z – volume: 139 start-page: 163 issue: 1 year: 2003 ident: ref7 article-title: PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect publication-title: British journal of pharmacology doi: 10.1038/sj.bjp.0705232 – start-page: 543 year: 2009 ident: ref21 article-title: Asthma and COPD – volume: 164 start-page: 1487 issue: 8 I year: 2001 ident: ref4 article-title: Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: Relationship with proliferation, apoptosis, and airway remodeling publication-title: American Journal of Respiratory and Critical Care Medicine doi: 10.1164/ajrccm.164.8.2101070 – volume: 19 start-page: 1033 issue: 8 year: 2005 ident: ref10 article-title: PPAR-gamma modulates allergic inflammation through up-regulation of PTEN publication-title: FASEB journal: official publication of the Federation of American Societies for Experimental Biology doi: 10.1096/fj.04-3309fje – volume: 351 start-page: 1106 issue: 11 year: 2004 ident: ref14 article-title: Thiazolidinediones publication-title: The New England journal of medicine doi: 10.1056/NEJMra041001 – volume: 182 start-page: 5816 issue: 9 year: 2009 ident: ref13 article-title: Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response publication-title: Journal of immunology doi: 10.4049/jimmunol.0803504 – volume: 83 start-page: 803 issue: 5 year: 1995 ident: ref31 article-title: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma publication-title: Cell doi: 10.1016/0092-8674(95)90193-0 – volume: 14 start-page: 902 issue: 4 year: 1999 ident: ref23 article-title: Development and validation of a questionnaire to measure asthma control publication-title: European Respiratory Journal doi: 10.1034/j.1399-3003.1999.14d29.x – volume: 38 start-page: 760 issue: 10 year: 1983 ident: ref24 article-title: Rapid method for measurement of bronchial responsiveness publication-title: Thorax doi: 10.1136/thx.38.10.760 – volume: 58 start-page: 778 issue: 9 year: 2003 ident: ref12 article-title: Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells publication-title: Thorax doi: 10.1136/thorax.58.9.778 – ident: ref26 – volume: 86 start-page: 49 issue: 1 year: 2009 ident: ref18 article-title: Bronchodilatory Effect of the PPAR-[gamma] Agonist Rosiglitazone in Smokers With Asthma publication-title: Clinical pharmacology and therapeutics doi: 10.1038/clpt.2009.41 – volume: 80 start-page: 105 issue: 2 year: 2006 ident: ref29 article-title: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome[ast] publication-title: Clinical pharmacology and therapeutics doi: 10.1016/j.clpt.2006.03.014 – volume: 115 start-page: 1265 issue: 5 year: 1999 ident: ref25 article-title: Validation of a Standardized Version of the Asthma Quality of Life Questionnaire* publication-title: Chest doi: 10.1378/chest.115.5.1265 – volume: 33 start-page: 1355 issue: 10 year: 2003 ident: ref27 article-title: Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial publication-title: Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology doi: 10.1046/j.1365-2222.2003.01777.x – volume: 280 start-page: 2550 issue: 4 year: 2005 ident: ref3 article-title: Differential Regulation of Chemokine Expression by Peroxisome Proliferator-activated Receptor Gamma Agonists publication-title: Journal of Biological Chemistry doi: 10.1074/jbc.M410616200 – ident: ref16 |
| SSID | ssj0053866 |
| Score | 2.3573346 |
| Snippet | Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether... Background Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine... BackgroundPeroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether... Background Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine... |
| SourceID | plos doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0160257 |
| SubjectTerms | Adult Aged Airway management Allergies Asthma Asthma - drug therapy Asthma - metabolism Asthma - physiopathology Biology and Life Sciences Bladder Bladder cancer Cancer Chemokine CCL2 - analysis Chemokine CXCL10 - analysis Clinical trials Confidence intervals Control methods Diabetes Double-Blind Method Double-blind studies Drug therapy Eosinophil cationic protein Eosinophil Cationic Protein - analysis Ethics Female Health risks Humans Hypoglycemic Agents - therapeutic use Inflammation Interferon IP-10 protein Male Medicine and Health Sciences Metabolism Middle Aged Monocyte chemoattractant protein 1 Nitric oxide Peroxisome proliferator-activated receptors Physical Sciences Pioglitazone Pneumonia - drug therapy Pneumonia - metabolism Pneumonia - physiopathology PPAR gamma - agonists PPAR gamma - metabolism Quality of Life Randomization Recruitment Research and Analysis Methods Respiratory Function Tests - methods Respiratory tract Respiratory tract diseases Sputum Sputum - metabolism Surveys and Questionnaires Thiazolidinediones - therapeutic use Time Factors Treatment Outcome Tumor necrosis factor-TNF Urinary bladder Vascular endothelial growth factor Vascular Endothelial Growth Factor A - analysis Young Adult |
| SummonAdditionalLinks | – databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbpwwELaqqIdeqqZ_IU0rV-qhPZCAAdv0RqJEvTRaRXvIDdnYTpAIRGHTQ16r79Fn6gz2ot0qUi69IWzEeGbMfIPtbwj5okzTCMdEzLROIEGReSwhUMSiKDKRQ_7hrC82Ic7P5eVludgo9YV7wjw9sFfcEXxZHYRQgYc4c-maMnHKCc7zJrPMyolsG1DPOpny32CYxZyHg3KZSI-CXQ5vh94eIqcaw3C0EYgmvn7kN-2G8TGs-e-WyY0YdPaKvAzgkVZe6F3yzPavyW6YniP9Gjikv70h7enM4k0HRwHl0cWiuoj__KbV1YBsuXTRDlfI0P0A0tK2pz_bztBqXF3fqO-0ooCsdWfjY4Chhl6o3gw37YM19MTvbe_gconO-5Ysz06XJz_iUFUhbgrGV3GeKiWUMokqmEO6PcNsozKpUpMYzUCt0qWM6dSiDY1UCldmnU7KTEvmsndkpwfB9ghNrGQl2JorY3NbFhqTpZzrwsgG0jwXkWyt4boJjONY-KKrp2U0AZmH11uNdqmDXSISz0_desaNJ_ofo_HmvsiXPd0AL6qDF9VPeVFE9tD06xeMNQAfhDZJlkfkYO0Ojzd_npthZuJyi-rtcO_7cAmemEbkvfeeWUgk3Qf5ZUTEll9tjWK7pW-vJ_ZvTFFTWe7_j2F_IC8AAHL8R86KA7Kzuru3H8nz5teqHe8-TVPqL3fFJ5k priority: 102 providerName: Directory of Open Access Journals – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELagcOAClJ82pSAjcYBD2sRJbIcLSqtWXKhW1R56i5zY3kZKk2Wz5dDX4j36TMwkTuiiCg7cothRZjIznhl78g0hH5QuS2GZ8FlRBJCgyNiX4Ch8kSSRiCH_sGZoNiHOzuTFRTpzG26dK6sc18R-odZtiXvkh-CJ0NcEUfxl-d3HrlF4uupaaDwkjxAlIepL92bjSgy2zLn7XS4S4aGTzsGybcwBIqsxdEp33FGP2o8op3Xb3Rdx_lk4eccTnT77Xx6ek6cuBqXZoDTb5IFpXpBtZ-Ud_eigqD-9JNXJBAZOW0shWKSzWXbu3_6k2aJF0F06q9oFAn3fALu0aui3qtY069aXV-ozzSgE6EVt_COIZjU9V41ur6obo-nxUCJfw-UcbeAVmZ-ezI-_-q45g18mjK_9OFRKKKUDlTCLqH2amVJFUoU60AUrIyNtyFgRGlQFLZXCA15bBGlUSGaj12SrAcJ2CQ2MZCmoDFfaxCZNCsy5Yl4kWpaQLVqPRKOI8tIBl2P_jDrvT-MEJDDDd8tRsLkTrEf86anlANzxj_lHKP1pLsJu9zfa1SJ3VpyDm7cQzwn8oziWtkwDq6zgPAZ2mZHcI7uoO-MLuvy3xD2yP-rE_cPvp2EwcDy1UY1pr4c5XIIqhx7ZGdRvIhKx-4F-6RGxoZgbXGyONNVlDyKOmW4o072_k_WGPIEIkeMmOkv2ydZ6dW3eksflj3XVrd711vYLsgs2ew priority: 102 providerName: ProQuest |
| Title | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27560168 https://www.proquest.com/docview/1814152034 https://www.proquest.com/docview/1814683861 https://pubmed.ncbi.nlm.nih.gov/PMC4999189 https://doaj.org/article/123f9377020448fc90faf7664c3e2e86 http://dx.doi.org/10.1371/journal.pone.0160257 |
| Volume | 11 |
| WOSCitedRecordID | wos000382258600009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Pb9MwFLbYxoELY_zYAqMyEgc4pCROYjvc2qoVaLSKSoUKl8iJ7S1Sl0xrt8P-Lf4P_ibeS9JCp02Iy1NU28qL_b36e7HzmZC3Sue5sEy4LMs8SFBk6EqYKFwRRYEIIf-wpjlsQkwmcj6Pkz-J4q0V_ED4H9o-7V5UpemiHhqAbIfssYBz3MI1Sr6s_3khdjlvP4-7r-XW9FOr9KOq6aJa3sUwb2-U_GvmGe3_r89PyOOWY9JeA4oD8sCUT8lBG8VL-q6Vmn7_jBTDjdg3rSwFMkiTpDd1f_2kvdMKRXVpUlSnKOR9AzehRUnHxULT3nJ1dq4-0h4FAp4tjNsHtqrpVJW6Oi9ujKaDZgv8Ai5niPHnZDYazgaf3PbwBTePGF-5oa-UUEp7KmIWVfk0M7kKpPK1pzOWB0Zan7HMNzjUWiqFC7g28-Igk8wGL8huCY4dEeoZyWKABFfahCaOMsypQp5FWuaQDVqHBOshSfNWmBzPx1ik9WqbgASl6bcUuzNtu9Mh7qbVRSPM8Y_6fRztTV2U1a5_gHFL2yhNYRq3wNcEfjEcSpvHnlVWcB7C4zIjuUOOECvrGyxT4EfIgLwgdMjxGj93F7_ZFEMA46qMKk111dThEqDrO-SwgdvGSdTmB_-lQ8QWELeeYrukLM5qkXDMZH0Zv7zf41fkEbA_ji_IWXRMdleXV-Y1eZhfr4rlZYfsiOk3tHNRWwlWDvwO2esPJ8m0U7-86NTxB_ak3wU79k7QiqS2X8Em0Q9okXweJ99_AzZeMW4 |
| linkProvider | Public Library of Science |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAwlegAFjgQFGAgkesiXOxS4SQt3YtGlbVU0V2lvkxHYXqUtK24HYf-KJ_8Fv4pxcyoomeNoDb1XspLbznVuO_R2AV0pnmbBcuDxNPQxQZOhKNBSuiKJAhBh_WFMXmxC9njw56fSX4Ht7Foa2VbY6sVLUuszoG_kmWiKyNV4Qfhh_dqlqFGVX2xIaNSwOzLevGLJN3-9_xPf7mvPdncH2nttUFXCziMczN_SVEkppT0XcEt2c5iZTgVS-9nTKs8BI63Oe-obmoKVSlJm0KYb-qeQ2wMfegJuoxn3aQSaOP7WKH1VHHDen8wLhbzZg2BiXhdkgIjdONvCS9auKBBCp6qicXuXg_rlP85Lh2733ny3ZfbjbeNisW4vECiyZ4gGsNDpsyt40RNtvH0K-M6c6Z6Vl6Aqzfr977P78wbrDkiiFWT8vh0RjfoGry_KCHeUjzbrT2emZese6DMOPdGTcLfTVNTtWhS7P8guj2XZ9AGCEPwck4Y9gcB0zXoXlAge2BswzkndQIGKlTWg6UUoRZRinkZYZxsLWgaBFRJI1tOxUHWSUVLlGgeFZvW4J4ShpcOSAO79rXNOS_KP_FoFt3pdIxasL5WSYNDoqQSfGorcq6Lx0KG3W8ayyIo5DnC43MnZgjaDa_sE0-Q0wB9ZbCF7d_HLejOqLclKqMOV53SeWKDm-A49rtM8HSZUJcPzSAbEgBwuzWGwp8tOKIp3ieF92nvx9WC_g9t7g6DA53O8dPIU76AvHlC7g0Toszybn5hncyr7M8unkeSXoDJJrlpJfZOuUng |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQIiXwbgtY4CRQIKHrIlzsYOEUNetYhpU1dSHvUVObHeRuqQ0HYj9LZ74E_wmzsmNFU3wtAfeqtptbfc7txyf7xDyUqo05YZxmyWJAwGK8G0BhsLmQeBxH-IPo-tmE3w0Eicn0XiN_GhrYfBaZasTK0WtihSfkffAEqGtcTy_Z5prEeP94fv5Zxs7SGGmtW2nUUPkSH_7CuFb-e5wH_7rV4wNDyaDD3bTYcBOAxYubd-VkkupHBkwg9RziulUekK6ylEJSz0tjMtY4mrcjxJSYpbSJE7kJYIZD772BrnJPQAxFqkPutsloEbCsKnU87jba4CxOy9yvYukbgzt4SVLWDUMQILVWVFe5ez-eWfzkhEc3v2Pj-8e2Wg8b9qvRWWTrOn8PtlsdFtJXzcE3G8ekOygo0CnhaHgItPxuH9s__xO-9MCqYbpOCumSG9-ASdNs5x-ymaK9svl6Zl8S_sUwpJkpu098OEVPZa5Ks6yC63ooC4MmMHLCUr-QzK5jh0_Ius5LGyLUEcLFoGghFJpX0dBgpGmHyaBEinEyMYiXouOOG3o2rFryCyucpAcwrb63GLEVNxgyiJ296l5TVfyj_l7CLxuLpKNV28Ui2nc6K4YnBsDXizHOmpfmDRyjDQ8DH3YLtMitMgWwrb9gTL-DTaL7LRwvHr4RTcMag1zVTLXxXk9JxQgRa5FHtfI7xaJHQtg_cIifEUmVnaxOpJnpxV1Osb3roi2_76s5-Q2CEf88XB09ITcARc5xCwCC3bI-nJxrp-SW-mXZVYunlUyT0l8zULyC68WnPk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+PPAR-%CE%B3+Agonist+Pioglitazone+in+Mild+Asthma%3A+A+Double-Blind+Randomized+Controlled+Trial&rft.jtitle=PloS+one&rft.au=Anderson%2C+J.+R.&rft.au=Mortimer%2C+K.&rft.au=Pang%2C+L.&rft.au=Smith%2C+K.+M&rft.date=2016-08-25&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=11&rft.issue=8&rft.spage=e0160257&rft_id=info:doi/10.1371%2Fjournal.pone.0160257&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pone_0160257 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |